Search for Clinical Trial Results
Primary Biliary Cholangitis - 29 Studies Found
Status | Study |
Completed |
Study Name: A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid Condition: Primary Biliary Cirrhosis Date: 2011-07-07 Interventions:
|
Active, not recruiting |
Study Name: The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland Condition: Primary Biliary Cirrhosis Date: 2016-07-25 |
Completed |
Study Name: Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis Condition: Primary Biliary Cirrhosis Date: 2008-12-08 Interventions:
|
Completed |
Study Name: Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Condition: Primary Biliary Cirrhosis Date: 2015-09-21 Interventions: Dietary Supplement: S-adenosyl-L-methionine Patients will be treated with S-adenosyl-L-methionine, table |
Completed |
Study Name: High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis Condition: Primary Biliary Cirrhosis Date: 2012-05-17 Interventions: Dietary Supplement: High protein high fiber diet A personalized high protein high fiber dietary plan wil |
NOT_YET_RECRUITING |
Study Name: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) Condition: Date: 2024-05-19 Interventions: Oral QD |
RECRUITING |
Study Name: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis Condition: Primary Biliary Cholangitis Date: 2024-05-19 Interventions: Seladelpar 10 mg one capsule daily for up to 36 months. |
RECRUITING |
Study Name: A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis Condition: Primary Biliary Cholangitis (PBC) Date: 2024-05-19 Interventions: Duration: up to an estimated 84-month (7-year) double-blind treatment period during which elafibranor 80 mg tablet will be administered once daily |
RECRUITING |
Study Name: IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) Condition: Primary Biliary Cholangitis Date: 2024-05-19 Interventions: Seladelpar 10 mg one capsule daily for up to 52 weeks |